Loading…
Leading global biologics CDMO, providing development and manufacturing services for biologic drugs including antibodies and vaccines.
Leading global biologics CDMO, providing development and manufacturing services for biologic drugs including antibodies and vaccines.
Is paid for project work at the development stage, then for manufacturing batches if the drug advances, so it wins customers early and keeps them through to commercial production. Revenue therefore follows clients' pipelines rather than any one drug. It is a sister company of WuXi AppTec, which was founded by the same team.
In one line: A Chinese Samsung Biologics/Catalent for biologics manufacturing.
Moat: narrow (scale, process know-how, customer qualification). Large global bioreactor capacity and regulatory-approved facilities make switching mid-program costly for clients.
Headquarters: Shanghai, China · Founded: 2014 · Employees: 13,252
Size Wuxi Bio (2269.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $25.0B, the 67th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$47.62 on 6 Nov 2026.
Performance Over six months the shares gained 43.1%, against +10.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 21.9% over the last twelve months (peer median +19.8%); the operating margin is 32.4% (peer median 24.6%).
Valuation It trades at 28.7× forward earnings against a peer median of 28.0× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points below its cost of capital (12.4% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$26.4B | HK$23.6B | HK$20.2B | HK$18.8B | HK$17.8B |
| Revenue growth | — | +17% | +8% | +6% | — |
| Gross profit | HK$12.5B | HK$10.9B | HK$8.30B | HK$7.54B | HK$7.82B |
| EBITDA | HK$10.6B | HK$9.10B | HK$6.77B | HK$5.88B | HK$6.27B |
| Net income | HK$5.59B | HK$5.32B | HK$3.64B | HK$3.76B | HK$5.14B |
| Free cash flow | HK$4.97B | HK$3.12B | HK$1.65B | HK$495M | -HK$365M |
| Capital expenditure | HK$5.28B | HK$4.05B | HK$4.17B | HK$4.69B | HK$6.82B |
| Total debt | n/a | HK$3.46B | HK$5.26B | HK$5.02B | HK$4.97B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Wuxi Bio 2269.HK | $25.0B | +43% | +22% | 32% | 28.7× | 21.8% |
| Samsung Biologics 207940.KS | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Fujifilm 4901.T | $24.9B | +14% | +7% | 10% | 14.1× | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Agc 5201.T | $6.33B | -15% | +6% | 6% | 12.6× | 4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2269.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | +9.4% | 3rd lowest of 21 |
| 6-month return | +43.1% | +10.4% | 7th highest of 21 |
| Distance from 52-week high | -17.9% | -14.1% | 10th lowest of 21 |
| Revenue growth (TTM) | +21.9% | +19.8% | 10th highest of 20 |
| Operating margin | 32.4% | 24.6% | 6th highest of 20 |
| Forward P/E | 28.7× | 28.0× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 21.8% | 9.0% | 4th most demanding of 17 |
| Growth delivered (Del g) | +30.2% | +17.1% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | -8.4 pp | -9.0 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | -0.2 pp | +2.1 pp | 8th lowest of 20 |
| EV / EBITDA | 18.1× | 16.3× | 5th most expensive of 12 |
| Net debt / EBITDA | -1.1× | 1.7× | 4th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuxi Bio 2269.HK | Hong Kong | $25.0B | +43% | +22% | 32% | 28.7× | 21.8% | +30.2% |
| United Therapeutics UTHR | United States | $24.1B | -1% | +2% | 44% | 22.0× | -0.4% | +16.5% |
| BioNTech SE Sponsored ADR BNTX | United States | $22.8B | -7% | -1% | -38% | n/a | 5.7% | +42.6% |
| Genmab A/S GMAB.CO | Denmark | $32.1B | +115% | +14% | 32% | 44.8× | 11.6% | +19.5% |
| Celltrion 068270.KS | South Korea | $34.3B | +10% | +40% | 32% | 34.1× | 8.3% | +17.6% |
| Neurocrine Biosciences NBIX | United States | $16.7B | +8% | +38% | 25% | 18.2× | -1.7% | +22.3% |
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | n/a | n/a | n/a |
| Natera NTRA | United States | $44.8B | +60% | +38% | -11% | n/a | n/a | n/a |
| Iqvia IQV | United States | $44.8B | +52% | +9% | 14% | 19.7× | 17.3% | +7.5% |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% | +7.6% |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% | +0.1% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 10.7× | 2.5% | +39.2% |
| Samsung Biologics 207940.KS | South Korea | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% | +31.4% |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 35.9× | 31.3% | +5.5% |
| Lonza LONN.SW | Switzerland | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% | +7.7% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | United States | $57.5B | +19% | +71% | 29% | n/a | 10.9% | +151.4% |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 10.3× | 6.5% | +12.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 37.3× | 7.2% | +2.3% |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 47.0× | 29.8% | +38.5% |